Call for Grant Applications (CFG) CFG-DermatologyFellowship-2024
AbbVie Independent Education (IE)

<table>
<thead>
<tr>
<th>Therapeutic Area/Disease State</th>
<th>Dermatology</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Focus</strong></td>
<td>Fellowship and/or internship programs directed at URM medical students, physicians, and scientists pursuing careers in dermatology</td>
</tr>
<tr>
<td><strong>Issue Date:</strong></td>
<td>December 12, 2023</td>
</tr>
<tr>
<td><strong>Due Date/CFG Close Date:</strong></td>
<td>February 16, 2024</td>
</tr>
<tr>
<td><strong>REMINDER:</strong> The AbbVie Grant Management System will be closed for new submissions during the month of December 2023. It will reopen on January 9, 2024.</td>
<td></td>
</tr>
</tbody>
</table>

**Background**

AbbVie is committed to supporting independent, high-quality evidence-based education with the most up-to-date information on current, new, and emerging therapies. This helps to expand knowledge, competence, and performance to improve quality of care for patients. We support initiatives that contribute to improving health equity and the elimination of health care disparities in underserved patient populations.

**Eligibility Criteria**

Grant applicants must be:

- US-based, registered in AbbVie’s Grant Management System at [grants.abbvie.com](http://grants.abbvie.com) with no outstanding reconciliations
- Accredited, US-based academic institutions & professional societies
- Institutions with fellowship and/or internship programs that include independent research and a strong mentoring program

**Transparency**

AbbVie and the AbbVie grant review and approval process complies with applicable laws, regulations, recommendations and guidance, including, without limitation: guidance from the Department of Health & Human Services Office of Inspector General (OIG), Pharmaceutical Research and Manufacturers of America (PhRMA), Advanced Medical Technology Association (AdvaMed), the Accreditation Council for Continuing Medical Education (ACCME), “National Physician Payment Transparency Program: OPEN PAYMENTS” (commonly known as the “Sunshine Act”), and internal AbbVie policies and procedures.

AbbVie, at its sole discretion, may disclose the details of funded independent medical education activities, including as may be required by federal, state, and/or local laws and regulations. This disclosure may include, but shall not be limited to, details of the activity and the grant amount.
Terms and Conditions

AbbVie reserves the right to approve or deny any or all grant applications received as a result of this Call for Grants (CFG) or to cancel, in part or in its entirety, this CFG. AbbVie is not responsible for any costs associated with this CFG submission.

Submission Directions

1. Please go to grants.abbvie.com and sign in. First-time users should click “Register.”

2. In the grant application:
   - STEP 1. Select Submit New Request to start the submission process.
   - STEP 2. Select the Education Requests button to continue the submission process.
   - STEP 3. Read the Request Submission Instructions and select Proceed to enter the request form.
   - STEP 4. Enter Request Information on the General Information Tab.
     - In the Activity Sub-Type field, select Fellowship
     - In the Program Title field, begin the title of the grant request as: CFG-DermatologyFellowship-2024
   - STEP 5. Continue entering requested information as outlined in the grant application, including document uploads.

3. If you have questions or require assistance, please contact:

   AbbVie Independent Education Department at 877-228-7177 or via email at abbviegrants@abbvie.com.

IMPORTANT: Grant applications submitted in response to this CFG after the due date will not be reviewed by the AbbVie Independent Education Department and will be automatically declined. In addition, grant applications must include the required information outlined in the Submission Directions. Failure to provide this information may result in the grant application being declined.

Decision Date and Notification

Once AbbVie has reached a decision about the grant application, a system-generated email notification will be sent. If the request is approved, the Authorized Signer identified in the grant application must log into the AbbVie grant management system to review and approve the Letter of Agreement. The Letter of Agreement must be electronically signed by all parties prior to the activity start date. Please do not consider any request approved until an email notification is received from AbbVie stating that the grant request is approved.
Call for Grant Details

<table>
<thead>
<tr>
<th>Therapeutic Area</th>
<th>Dermatology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Target Audience</td>
<td>URM medical students, physicians, and scientists in dermatology</td>
</tr>
<tr>
<td>Geographic Scope</td>
<td>USA</td>
</tr>
<tr>
<td>Due Date/CFG Close Date</td>
<td>February 16, 2024</td>
</tr>
<tr>
<td>Anticipated Notification</td>
<td>April 2024</td>
</tr>
<tr>
<td>Budget</td>
<td>$500,000</td>
</tr>
</tbody>
</table>
| Other Criteria | • The fellow/intern must demonstrate financial need.  
• Scientific and/or mechanistic research in inflammatory skin disorders is preferred.  
• Fellow/Intern time spent in the clinical setting that is supported through grant funds must not be billed as patient care. |

Statement of Need

There is an urgent need to address racial and minority disparities, including those related to healthcare. In dermatology, these disparities are particularly pronounced. According to the American Academy of Dermatology, only 3% of dermatologists are Black or African American despite this minority representing over 13% of the US population. Under-represented minorities (URM)—particularly African American patients—tend to feel more satisfied with their care in race concordant physician-patient relationships; thus, the lack of minority representation within dermatology leads to a reluctance to seek care. This creates a cycle of disparity as dermatologists have less experience treating these groups, leading to worse long-term outcomes. Finally, the lack of diversity within dermatology means there are few URM investigators to enroll URM patients, exacerbating the lack of diversity within clinical trials and creating data gaps in this patient population.

There is an urgent need to increase the number of practicing URM dermatologists and research scientists focused on dermatology research. This requires developing a diverse pipeline of URM medical students, physicians, and scientists. Therefore, it is the intent of AbbVie to support research fellowship and/or internship programs directed at URM medical students, physicians, and scientists pursuing careers in dermatology.

References